Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.62 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.58 |
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504686 | 1.00 | ADAM17 (0.62) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL10276770 | 0.92 | ADAM17 (0.62) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL10276145 | 0.92 | ADAM17 (0.62) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504822 | 0.91 | ADAM17 (0.51) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1503620 | 0.87 | ADAM17 (0.55) | ADAM17ADAM10MMP3MMP1ALDH1A1 | |
| SCHEMBL1503675 | 0.87 | ADAM17 (0.55) | ADAM17ADAM10MMP3MMP1ALDH1A1 | |
| SCHEMBL1503642 | 0.85 | ADAM17 (0.53) | ADAM17ALDH1A1 | |
| SCHEMBL1503541 | 0.85 | ADAM17 (0.53) | ADAM17ALDH1A1 | |
| SCHEMBL1504730 | 0.85 | ADAM17 (0.44) | ADAM17ADAM10MMP3ADAM9ALDH1A1 | |
| SCHEMBL1504911 | 0.85 | ADAM17 (0.81) | ADAM17ADAM10MMP3ADAM9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011033009-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |